SCHEDULE: Citius Pharma Boosts Stake in Oncology Unit to 77.9%

Citius Pharmaceuticals, Inc. increased its beneficial ownership in Citius Oncology, Inc. to 77.9% following a registered direct offering.

Summary

• Citius Pharmaceuticals, Inc. (the "Reporting Person") beneficially owns 66,049,615 shares of Citius Oncology, Inc. common stock.
• This ownership represents approximately 77.9% of Citius Oncology, Inc.'s outstanding common stock.
• The percentage is calculated based on 84,797,846 shares of common stock outstanding as of December 10, 2025.
• The change in ownership resulted from Citius Oncology, Inc. selling and issuing 1,284,404 shares of its common stock in a registered direct offering on December 10, 2025.
• This document is Amendment No. 3 to the original Schedule 13D filed on August 16, 2024, with previous amendments on July 25, 2025, and September 12, 2025.

Sentiment

Score: 6

Explanation: The filing reports a routine ownership update following a capital raise. The parent company increasing its stake in the subsidiary can be seen as a positive sign of confidence, but the share issuance also implies dilution for other shareholders. It's a neutral to slightly positive event from a strategic perspective, but not overwhelmingly so.

Positives

• Increased ownership by Citius Pharmaceuticals, Inc. in its oncology subsidiary could signal strong confidence in the subsidiary's future prospects and strategic alignment.
• Citius Oncology, Inc. successfully raised capital through the issuance of 1,284,404 shares in a registered direct offering.

Negatives

• The increase in the parent company's stake could potentially reduce the float for minority shareholders, impacting liquidity.
• Existing minority shareholders experienced dilution due to the issuance of 1,284,404 new shares in the registered direct offering.

Future Outlook

No specific future outlook or guidance is provided in this ownership disclosure.

Management Comments

• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct." Leonard Mazur, Chief Executive Officer of Citius Pharmaceuticals, Inc.

Industry Context

This filing reflects a parent company increasing its stake in a subsidiary, a common strategy for consolidating control or demonstrating commitment to a specific business unit, particularly in specialized sectors like oncology where long-term investment and strategic alignment are crucial.

Comparison to Industry Standards

• Increased ownership by a parent company in a subsidiary is a standard corporate action, often seen when a parent seeks to consolidate control, streamline operations, or provide further capital to a promising venture.
• The 77.9% stake represents a significant majority, indicating strong control by Citius Pharmaceuticals over Citius Oncology, which is typical for a strategic subsidiary.
• Registered direct offerings are a common method for public companies to raise capital efficiently, often involving institutional investors.

Related Party Transactions

• The transaction involves Citius Pharmaceuticals, Inc. increasing its stake in Citius Oncology, Inc., which is a related party transaction by nature of the parent-subsidiary relationship.

Stakeholder Impact

• Shareholders of Citius Pharmaceuticals, Inc. gain increased control and potential upside from Citius Oncology's future performance.
• Minority shareholders of Citius Oncology, Inc. experienced dilution of their existing holdings due to the issuance of new shares.
• Citius Oncology, Inc. received capital from the registered direct offering to fund its operations or development initiatives.

Key Dates

Recommendation

This filing primarily details an ownership change and a capital raise. While the parent company's increased stake signals confidence, the dilution from the offering balances this. Without further financial or operational details, a 'hold' recommendation is appropriate as this filing alone doesn't present a strong catalyst for a 'buy' or 'sell' decision, but rather confirms ongoing strategic alignment and funding.

Keywords

Citius Oncology, Citius Pharmaceuticals, Schedule 13D, beneficial ownership, common stock, registered direct offering, equity stake, SEC filing, oncology